Evaluation of the Seroprevalence of Infectious Diseases in 2,445 in vitro Fertilization Cycles

Abstract

Objective To evaluate the seroprevalence of positive markers for syphilis, human immunodeficiency virus (HIV) I and II, human T cell lymphotropic virus (HTLV) I and II, and hepatitis B and C among women undergoing in vitro fertilization (IVF).

Methods We conducted a retrospective analysis among patients who underwent IVF, between January 2013 and February 2016, and who had complete screening records.

Results We analyzed 1,008 patients who underwent IVF, amounting to 2,445 cycles. Two patients (0.2%) tested positive for HIV I and II and none for HTLV I and II. Three patients (0.3%) had positive screening for syphilis, and two (0.2%) had positive hepatitis C antibody test (anti-HCV). A positive hepatitis B virus surface antigen (HbsAg) test was observed in 4 patients (0.4%), while 47 (4.7%) patients were positive for IgG antibody to hepatitis B core antigen (anti-HbC IgG), and only 1 (0.1%) was positive for IgM antibody to hepatitis B core antigen (anti-HbC IgM). The anti-HbS test was negative in 659 patients (65.3%). Only 34.7% of the patients had immunity against the Hepatitis B virus. Patients with an anti-HbS negative result were older than those with a hepatitis B test (anti-HbS) positive result (36.3 versus 34.9; p < 0.001).

Conclusion The present study showed lower infection rates than the Brazilian ones for the diseases studied in patients undergoing IVF. Only a few patients were immunized against hepatitis B.

Resumo

Objetivo Avaliar a soroprevalência de marcadores positivos para sífilis, vírus da imunodeficiência humana (HIV) I e II, vírus linfotrópicos de células T humanas (HTLV) I e II e hepatite B e C em mulheres submetidas a fertilização in vitro (FIV).

Métodos Realizamos uma análise retrospectiva entre as pacientes submetidas a FIV, entre janeiro de 2013 e fevereiro de 2016, e que possuíam prontuários completos.

Resultados Foram analisadas 1.008 pacientes submetidas a FIV, totalizando 2,445 ciclos. Duas pacientes (0,2%) apresentaram resultado positivo para HIV I e II, e nenhuma para HTLV I e II. Três pacientes (0,3%) apresentaram triagem positiva para sífilis, e duas (0,2%) apresentaram teste de pesquisa de anticorpos anti-HCV (anti-HCV) positivo. Um teste de antígeno de superfície do vírus da hepatite B (HbsAg) positivo foi observado em 4 pacientes (0,4%), enquanto 47 (4,7%) pacientes foram positivas para anticorpos IgG contra o antígeno de superfície da hepatite B (IgG anti-HbC), e apenas 1 (0,1%) foi positiva para anticorpos IgM contra o antígeno central da hepatite B (IgM anti-HbC). O teste de anticorpos contra hepatite B (anti-HbS) foi negativo em 659 pacientes (65,3%). Apenas 34,7% das pacientes tinham imunidade contra o vírus da hepatite B. Pacientes com resultado negativo anti-HbS eram mais velhas do que aquelas com resultado positivo anti-HbS (36,3 versus 34,9; p < 0,001).

Conclusão Este estudo mostrou taxas de infecção inferiores às taxas brasileiras para as doenças estudadas em pacientes submetidas à FIV. Apenas alguns pacientes foram imunizados contra a hepatite B.

Keywords

fertilization in vitro - human immunodeficiency virus - syphilis - hepatitis B - hepatitis C - human T-lymphotropic virus 1

Palavras-chave

fertilização in vitro - vírus da imunodeficiência humana - sífilis - hepatite B - hepatite C - vírus linfotrópico T humano 1

Publication History

Received: 05 July 2020

Accepted: 06 January 2021

Article published online:
15 April 2021

• References

• 1 Jain T, Grainger DA, Ball GD. et al. 30 years of data: impact of the United States in vitro fertilization data registry on advancing fertility care. Fertil Steril 2019; 111 (03) 477-488 DOI: 10.1016/j.fertnstert.2018.11.015.
• 2 Haas D, Chvatal R, Reichert B. et al. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. Arch Gynecol Obstet 2012; 286 (03) 667-670 DOI: 10.1007/s00404-012-2361-z.
• 3 World Health Organization. Report on global sexually transmitted infection surveillance. Geneva: WHO; 2018
• 4 Gold E, Mizrachi Y, Shalev A. et al. Screening for blood born viruses in assisted reproduction: is annual testing necessary?. Arch Gynecol Obstet 2019; 299 (06) 1709-1713 DOI: 10.1007/s00404-019-05112-0.
• 5 Cavalcante GMCC, Amaral WN. Soroprevalência de sífilis em pacientes submetidos à fertilização assistida. Reprod Clim. 2014; 29 (01) 3-7 DOI: 10.1016/j.recli.2014.05.004.
• 6 Practice Committee of American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril 2012; 98 (02) 302-307 DOI: 10.1016/j.fertnstert.2012.05.032.
• 7 Yakass MB, Woodward BJ, Otoo MA, Hiadzi EK. Prevalence of blood borne viruses in IVF: an audit of a fertility Centre. JBRA Assist Reprod 2016; 20 (03) 132-136 DOI: 10.5935/1518-0557.20160030.
• 8 Hart R, Khalaf Y, Lawson R, Bickerstaff H, Taylor A, Braude P. Screening for HIV, hepatitis B and C infection in a population seeking assisted reproduction in an inner London hospital. BJOG 2001; 108 (06) 654-656 DOI: 10.1111/j.1471-0528.2001.00146.x.
• 9 Monich AG, Dantas TW, Fávero KB. et al. Blood discard rate in a blood center in Curitiba - Brazil. Ten years of study. Transfus Apheresis Sci 2017; 56 (02) 130-134 DOI: 10.1016/j.transci.2016.10.007.
• 10 David MC, Ha SH, Paynter S, Lau C. A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination. Vaccine 2015; 33 (48) 6564-6569 DOI: 10.1016/j.vaccine.2015.09.051.
• 11 Malm K, Ekermo B, Hillgren K, Britton S, Fredlund H, Andersson S. Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scand J Infect Dis 2012; 44 (11) 852-859 DOI: 10.3109/00365548.2012.689847.